Hepatobiliary transporters in the pharmacology and toxicology of anticancer drugs

Frontiers in Bioscience

Volumn 14, Issue 11, 2009, Pages 4257-4280

  Marin, Jose J G ^a,b   Briz, Oscar ^b   Perez, Maria J ^b   Romero, Marta R ^a   Monte, Maria J ^a  

^a Laboratory of Experimental Hepatology and Drug Targeting (HEVEFARM)   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

ABC proteins; Cancer; Carrier; Chemotherapy; Resistance; Review; Transport; Tumor; Uptake

Indexed keywords

ANTINEOPLASTIC AGENT; CARRIER PROTEIN;

DRUG EFFECT; HEPATOBILIARY SYSTEM; HUMAN; LIVER; METABOLISM; REVIEW;

ANTINEOPLASTIC AGENTS; BILIARY TRACT; CARRIER PROTEINS; HUMANS; LIVER;

EID: 63849331205     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3527     Document Type: Review

References (279)

1. B. Hagenbuch and P. J. Meier: Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO super-family, new nomenclature and molecular/functional properties. Pflugers Arch 447, 653-665(2004) (Pubitemid 38241451)
2. B. Hagenbuch and P. J. Meier: The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta 1609, 1-18(2003) (Pubitemid 36044060)
3. Y. Cui, J. Konig, I. Leier, U. Buchholz and D. Keppler: Hepatic uptake of bilirrubin and its conjugates by the human organic anion-transporting polypeptide SLC21A6. J Biol Chem 276, 9626-9630(2001)
4. O. Briz, M. A. Serrano, R. I. Macias, J. Gonzalez-Gallego and J. J. G. Marin: Role of organic aniontransporting polypeptides, OATP-A, OATP-C and OATP-8 in the human placenta-maternal liver tandem excretory pathway for foetal bilirubin. Biochem J 371, 897-905(2003) (Pubitemid 36578888)
5. G. A. Kullak-Ublick, M. G. Ismair, B. Stieger, L. Landmann, R. Huber, F. Pizzagalli, K. Fattinger, P. J. Meier and B. Hagenbuch: Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 120, 525-533(2001) (Pubitemid 32147650)
6. E. Jigorel, M. Le Vee, C. Boursier-Neyret, M. Bertrand and O. Fardel: Functional expression of sinusoidal drug transporters in primary human and rat hepatocytes. Drug Metab Dispos 33, 1418-1422(2005) (Pubitemid 41323987)
7. I. Badagnani, R. A. Castro, T. R. Taylor, C. M. Brett, C. C. Huang, D. Stryke, M. Kawamoto, S. J. Johns, T. E. Ferrin, E. J. Carlson, E. G. Burchard and K. M. Giacomini: Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther 318, 521-529(2006) (Pubitemid 44061225)
8. T. Abe, M. Unno, T. Onogawa, T. Tokui, T. N. Kondo, R. Nakagomi, H. Adachi, K. Fujiwara, M. Okabe, T. Suzuki, K. Nunoki, E. Sato, M. Kakyo, T. Nishio, J. Sugita, N. Asano, M. Tanemoto, M. Seki, F. Date, K. Ono, Y. Kondo, K. Shiiba, M. Suzuki, H. Ohtani, K. Shimosegawa, K. Iinuma, H. Nagura, S. Ito and S. Matsuno: LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology 120, 1689-1699(2001) (Pubitemid 32523487)
9. T. Nozawa, H. Minami, S. Sugiura, A. Tsuji and I. Tamai: Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos 33, 434-439(2005) (Pubitemid 40279945)
10. N. F. Smith, M. R. Acharya, N. Desai, W. D. Figg, A. Sparreboom, B. Hagenbuch, B. Ugele, P. J. Meier and T. Stallmach: Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther 4, 815-818(2005)
11. N. F. Smith, S. Marsh, T. J. Scott-Horton, A. Hamada, S. Mielke, K. Mross, W. D. Figg, J. Verweij, H. L. McLeod and A. Sparreboom: Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin Pharmacol Ther 81, 76-82(2007) (Pubitemid 46050869)
12. M. Dogruel, J. E. Gibbs and S. A. Thomas: Hydroxyurea transport across the blood-brain and blood-cerebrospinal fluid barriers of the guinea-pig. J Neurochem 87, 76-84(2003) (Pubitemid 37210641)
13. B. Hagenbuch, B. Stieger, M. Foguet, H. Lubbert and P. J. Meier: Functional expression cloning and characterization of the hepatocyte Na+/bile acid cotransport system. Proc Natl Acad Sci U S A 88, 10629-10633(1991) (Pubitemid 21915890)
14. B. Hagenbuch and P. J. Meier: Molecular cloning, chromosomal localization and functional characterization of a human liver Na+/bile acid cotransporter. J Clin Invest 93, 1326-1331(1994) (Pubitemid 24087193)
15. P. J. Meier, U. Eckhardt, A. Schroeder, B. Hagenbuch and B. Stieger: Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liver. Hepatology 26, 1667-1677(1997) (Pubitemid 27520039)
16. E. C. Friesema, R. Docter, E. P. Moerings, B. Stieger, B. Hagenbuch, P. J. Meier, E. P. Krenning, G. Hennemann and T. J. Visser: Identification of thyroid hormone transporters. Biochem Biophys Res Commun 254, 497-501(1999) (Pubitemid 29290429)
17. M. H. Wong, P. Oelkers, A. L. Craddock and P. A. Dawson: Expression cloning and characterization of the hamster ileal sodium-dependent bile acid transporter. J Biol Chem 269, 1340-1347(1994)
18. B. L. Shneider, P. A. Dawson, D. M. Christie, W. Hardikar, M. H. Wong and F. J. Suchy: Cloning and molecular characterization of the ontogeny of a rat ileal sodium-dependent bile acid transporter. J Clin Invest 95, 745-754(1995)
19. M. H. Wong, P. Oelkers and P. A. Dawson: Identification of a mutation in the ileal sodiumdependent bile acid transporter gene that abolishes transport activity. J Biol Chem 270, 27228-27234(1995)
20. D. M. Christie, P. A. Dawson, S. Thevananther and B. L. Shneider: Comparative analysis of the ontogeny of a sodium-dependent bile acid transporter in rat kidney and ileum. Am J Physiol 271, G377-G385 (1996)
21. A. L. Craddock, M. V. Love, R. W. Daniel, L. C. Kirby, H. C. Walters, M. H. Wong and P. A. Dawson: Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter. Am J Physiol 274, G157-G169 (1998)
22. G. A. Kullak-Ublick, J. Glasa, C. Boker, M. Oswald, U. Grutzner, B. Hagenbuch, B. Stieger, P. J. Meier, U. Beuers, W. Kramer, G. Wess and G. Paumgartner: Chlorambucil-taurocholate is transported by bile acid carriers expressed in human hepatocellular carcinomas. Gastroenterology 113, 1295-1305(1997) (Pubitemid 27418984)
23. O. Briz, M. A. Serrano, N. Rebollo, B. Hagenbuch, P. J. Meier, H. Koepsell and J. J. G. Marin: Carriers involved in targeting the cytostatic bile acid-cisplatin derivatives cis-diammine-chlorocholylglycinate-platinum (II) and cis-diamminebisurso deoxycholate-platinum (II) toward liver cells. Mol Pharmacol 61, 853-860(2002) (Pubitemid 34273165)
24. H. Miyazaki, T. Sekine and H. Endou: The multispecific organic anion transporter family: properties and pharmacological significance. Trends Pharmacol Sci 25, 654-662(2004) (Pubitemid 39458172)
25. W. Sun, R. R. Wu, P. D. van Poelje and M. D. Erion: Isolation of a family of organic anion transporters from human liver and kidney. Biochem Biophys Res Commun 283, 417-422(2001) (Pubitemid 32924708)
26. T. Sekine, S. H. Cha, M. Tsuda, N. Apiwattanakul, N. Nakajima, Y. Kanai and H. Endou: Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett 429, 179-182(1998) (Pubitemid 28288205)
27. G. A. Kullak-Ublick, U. Beuers and G. Paumgartner: Hepatobiliary transport. J Hepatol 32, 3-18(2000) (Pubitemid 30123620)
28. M. Takeda, S. Khamdang, S. Narikawa, H. Kimura, M. Hosoyamada, S. H. Cha, T. Sekine and H. Endou: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther 302, 666-671(2002) (Pubitemid 34787234)
29. Y. Kobayashi, N. Ohshiro, R. Sakai, M. Ohbayashi, N. Kohyama and T. Yamamoto: Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol 57, 573-578(2005) (Pubitemid 40562396)
30. E. J. Jeong, H. Lin and M. Hu: Disposition mechanisms of raloxifene in the human intestinal Caco-2 model. J Pharmacol Exp Ther 310, 376-385(2004) (Pubitemid 38812733)
31. S. Mori, S. Ohtsuki, H. Takanaga, T. Kikkawa, Y. S. Kang and T. Terasaki: Organic anion transporter 3 is involved in the brain-to-blood efflux transport of thiopurine nucleobase analogs. J Neurochem 90, 931-941(2004) (Pubitemid 39099975)
32. E. S. Ho, D. C. Lin, D. B. Mendel and T. Cihlar: Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J Am Soc Nephrol 11, 383-393(2000) (Pubitemid 30115068)
33. H. Koepsell, K. Lips and C. Volk: Polyspecific organic cation transporters: Structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 24, 1227-1251(2007) (Pubitemid 46876495)
34. J. W. Jonker and A. H. Schinkel: Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J Pharmacol Exp Ther 308, 2-9(2004) (Pubitemid 38090693)
35. L. Zhang, M. J. Dresser, A. T. Gray, S. C. Yost, S. Terashita and K. M. Giacomini: Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol 51, 913-921(1997) (Pubitemid 27249124)
36. S. Zhang, K. S. Lovejoy, J. E. Shima, L. L. Lagpacan, Y. Shu, A. Lapuk, Y. Chen, T. Komori, J. W. Gray, X. Chen, S. J. Lippard and K. M. Giacomini: Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res 66, 8847-8857(2006) (Pubitemid 44449203)
37. G. Ciarimboli, T. Ludwig, D. Lang, H. Pavenstadt, H. Koepsell, H. J. Piechota, J. Haier, U. Jaehde, J. Zisowsky and E. Schlatter: Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol 167, 1477-1484(2005) (Pubitemid 41713303)
38. A. Yonezawa, S. Masuda, K. Nishihara, I. Yano, T. Katsura and K. Inui: Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. Biochem Pharmacol 70, 1823-1831(2005) (Pubitemid 41612013)
39. M. Aouida, A. Leduc, H. Wang and D. Ramotar: Characterization of a transport and detoxification pathway for the antitumour drug bleomycin in Saccharomyces cerevisiae. Biochem J 384, 47-58(2004) (Pubitemid 39564160)
40. H. Koepsell: Organic cation transporters in intestine, kidney, liver, and brain. Annu Rev Physiol 60, 243-266(1998) (Pubitemid 28157873)
41. D. L. White, V. A. Saunders, P. Dang, J. Engler, A. C. Zannettino, A. C. Cambareri, S. R. Quinn, P. W. Manley and T. P. Hughes: OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 108, 697-704(2006) (Pubitemid 44061372)
42. M. Okabe, M. Unno, H. Harigae, M. Kaku, Y. Okitsu, T. Sasaki, T. Mizoi, K. Shiiba, H. Takanaga, T. Terasaki, S. Matsuno, I. Sasaki, S. Ito and T. Abe: Characterization of the organic cation transporter SLC22A16: a doxorubicin importer. Biochem Biophys Res Commun 333, 754-762(2005) (Pubitemid 40854224)
43. G. H. Elgemeie: Thioguanine, mercaptopurine: their analogs and nucleosides as antimetabolites. Curr Pharm Des 9, 2627-2642(2003)
44. C. J. Allegra and J. L. Grem: Antimetabolites. In: V. T. De-Vita Jr, ed. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott-Raven 490-498 (1997)
45. A. Felipe, R. Valdes, B. Santo, J. Lloberas, J. Casado and M. Pastor-Anglada: Na+-dependent nucleoside transport in liver: two different isoforms from the same gene family are expressed in liver cells. Biochem J 330, 997-1001(1998) (Pubitemid 28112008)
46. A. K. Fotoohi, M. Lindqvist, C. Peterson and F. Albertioni: Involvement of the concentrative nucleoside transporter 3 and equilibrative nucleoside transporter 2 in the resistance of T-lymphoblastic cell lines to thiopurines. Biochem Biophys Res Commun 343, 208-215(2006)
47. K. Nagai, K. Nagasawa, Y. Kihara, H. Okuda and S. Fujimoto: Anticancer nucleobase analogues 6-mercaptopurine and 6-thioguanine are novel substrates for equilibrative nucleoside transporter 2. Int J Pharm 333, 56-61(2007) (Pubitemid 46283266)
48. J. R. Mackey, S. Y. Yao, K. M. Smith, E. Karpinski, S. A. Baldwin, C. E. Cass and J. D. Young: Gemcitabine transport in Xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters. J Natl Cancer Inst 91, 1876-1881(1999)
49. J. Garcia-Manteiga, M. Molina-Arcas, F. J. Casado, A. Mazo and M. Pastor-Anglada: Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2', 2'-difluorodeoxycytidine-induced cytotoxicity. Clin Cancer Res 9, 5000-5008(2003) (Pubitemid 37323307)
50. J. H. Gray, R. P. Owen and K. M. Giacomini: The concentrative nucleoside transporter family, SLC28. Pflugers Arch 447, 728-734(2004) (Pubitemid 38241458)
51. J. F. Mata, J. M. Garcia-Manteiga, M. P. Lostao, S. Fernandez-Veledo, E. Guillen-Gomez, I. M. Larrayoz, J. Lloberas, F. J. Casado and M. Pastor-Anglada: Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5'-deoxy-5-fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug. Mol Pharmacol 59, 1542-1548(2001) (Pubitemid 32510121)
52. R. Safaei and S. B. Howell: Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit Rev Oncol Hematol 53, 13-23(2005) (Pubitemid 39656107)
53. S. Ishida, J. Lee, D. J. Thiele and I. Herskowitz: Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci U S A 99, 14298-14302(2002) (Pubitemid 35257666)
54. M. J. Monte, M. R. Ballestero, O. Briz, M. J. Perez and J. J. G. Marin: Pro-apoptotic effect on normal and tumor intestinal cells of cytostatic drugs with enterohepatic organotropism. J Pharmacol Exp Therap 315, 24-35(2005) (Pubitemid 41380494)
55. J. Lin, D. A. Raoof, D. G. Thomas, J. K. Greenson, T. J. Giordano, G. S. Robinson, M. J. Bourner, C. T. Bauer, M. B. Orringer and D. G. Beer: L-type amino acid transporter-1 overexpression and melphalan sensitivity in Barrett's adenocarcinoma. Neoplasia 6, 74-84(2004) (Pubitemid 38391950)
56. Y. Takada, N. H. Greig, D. T. Vistica, S. I. Rapoport and Q. R. Smith: Affinity of antineoplastic amino acid drugs for the large neutral amino acid transporter of the blood-brain barrier. Cancer Chemother Pharmacol 29, 89-94(1991)
57. N. H. Greig, S. Momma, D. J. Sweeney, Q. R. Smith and S. I. Rapoport: Facilitated transport of melphalan at the rat blood-brain barrier by the large neutral amino acid carrier system. Cancer Res 47, 1571-1576(1987) (Pubitemid 17044485)
58. G. Decorti, I. Peloso, D. Favarin, F. B. Klugmann, L. Candussio, E. Crivellato, F. Mallardi and L. Baldini: Handling of doxorubicin by the LLC-PK1 kidney epithelial cell line. J Pharmacol Exp Ther 286, 525-530(1998) (Pubitemid 28318029)
59. R. Regev, D. Yeheskely-Hayon, H. Katzir and G. D. Eytan: Transport of anthracyclines and mitoxantrone across membranes by a flip-flop mechanism. Biochem Pharmacol 70, 161-169(2005) (Pubitemid 40797880)
60. A. Zarubica, D. Trompier and G. Chimini: ABCA1, from pathology to membrane function. Pflugers Arch 453, 569-579(2007) (Pubitemid 46192530)
61. C. Albrecht and E. Viturro: The ABCA subfamily-gene and protein structures, functions and associated hereditary diseases. Pflugers Arch 453, 581-589(2007) (Pubitemid 46192531)
62. S. Tsuruoka, K. Ishibashi, H. Yamamoto, M. Wakaumi, M. Suzuki, G. J. Schwartz, M. Imai and A. Fujimura: Functional analysis of ABCA8, a new drug transporter. Biochem Biophys Res Commun 298, 41-45(2002) (Pubitemid 35205384)
63. N. M. Laing, M. G. Belinsky, G. D. Kruh, D. W. Bell, J. T. Boyd, L. Barone, J. R. Testa and K. D. Tew: Amplification of the ATP-binding cassette 2 transporter gene is functionally linked with enhanced efflux of estramustine in ovarian carcinoma cells. Cancer Res 58, 1332-1337(1998) (Pubitemid 28193584)
64. G. G. Wulf, S. Modlich, N. Inagaki, D. Reinhardt, R. Schroers, F. Griesinger and L. Trumper: ABC transporter ABCA3 is expressed in acute myeloid leukemia blast cells and participates in vesicular transport. Haematologica 89, 1395-1397(2004) (Pubitemid 39540580)
65. T. C. Islam, A. C. Asplund, J. M. Lindvall, L. Nygren, J. Liden, E. Kimby, B. Christensson, C. I. Smith and B. Sander: High level of cannabinoid receptor 1, absence of regulator of G protein signalling 13 and differential expression of Cyclin D1 in mantle cell lymphoma. Leukemia 17, 1880-1890(2003) (Pubitemid 37185266)
66. N. Kartner, J. R. Riordan and V. Ling: Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 221, 1285-1288(1983) (Pubitemid 13005502)
67. L. M. Chan, S. Lowes and B. H. Hirst: The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci 21, 25-51(2004) (Pubitemid 38050202)
68. I. Pastan, M. M. Gottesman, K. Ueda, E. Lovelace, A. V. Rutherford and M. C. Willingham: A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc Natl Acad Sci U S A 85, 4486-4490(1988)
69. M. Muller, R. Mayer, U. Hero and D. Keppler: ATP-dependent transport of amphiphilic cations across the hepatocyte canalicular membrane mediated by mdr1 P-glycoprotein. FEBS Lett 343, 168-172(1994) (Pubitemid 24126669)
70. C. J. Matheny, M. W. Lamb, K. R. Brouwer and G. M. Pollack: Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation. Pharmacotherapy 21, 778-796(2001) (Pubitemid 32606791)
71. D. de Graaf, R. C. Sharma, E. B. Mechetner, R. T. Schimke and I. B. Roninson: P-glycoprotein confers methotrexate resistance in 3T6 cells with deficient carrier-mediated methotrexate uptake. Proc Natl Acad Sci U S A 93, 1238-1242(1996) (Pubitemid 26052872)
72. H. Zeng, Z. P. Lin and A. C. Sartorelli: Resistance to purine and pyrimidine nucleoside and nucleobase analogs by the human MDR1 transfected murine leukemia cell line L1210/VMDRC.06. Biochem Pharmacol 68, 911-921(2004) (Pubitemid 39044518)
73. P. Wils, V. Phung-Ba, A. Warnery, D. Lechardeur, S. Raeissi, I. J. Hidalgo and D. Scherman: Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. Biochem Pharmacol 48, 1528-1530(1994) (Pubitemid 24318161)
74. U. S. Rao, R. L. Fine and G. A. Scarborough: Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol 48, 287-292(1994)
75. E. Schurr, M. Raymond, J. C. Bell and P. Gros: Characterization of the multidrug resistance protein expressed in cell clones stably transfected with the mouse mdr1 cDNA. Cancer Res 49, 2729-2733(1989)
76. X. P. Zhang, M. K. Ritke, J. C. Yalowich, M. L. Slovak, J. P. Ho, K. I. Collins, T. Annable, R. J. Arceci, F. E. Durr and L. M. Greenberger: P-glycoprotein mediates profound resistance to bisantrene. Oncol Res 6, 291-301(1994) (Pubitemid 24370312)
77. C. B. Hendricks, E. K. Rowinsky, L. B. Grochow, R. C. Donehower and S. H. Kaufmann: Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res 52, 2268-2278(1992)
78. F. X. Mahon, F. Belloc, V. Lagarde, C. Chollet, F. Moreau-Gaudry, J. Reiffers, J. M. Goldman and J. V. Melo: MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 101, 2368-2373(2003) (Pubitemid 36304670)
79. S. Hoffmeyer, O. Burk, O. von Richter, H. P. Arnold, J. Brockmoller, A. Johne, I. Cascorbi, T. Gerloff, I. Roots, M. Eichelbaum and U. Brinkmann: Functional polymorphisms of the human multidrugresistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 97, 3473-3478(2000) (Pubitemid 30183327)
80. Z. C. Gatmaitan and I. M. Arias: Structure and function of P-glycoprotein in normal liver and small intestine. Adv Pharmacol 24, 77-97(1993)
81. E. G. Schuetz, W. T. Beck and J. D. Schuetz: Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 49, 311-318(1996) (Pubitemid 26066117)
82. V. J. Wacher, J. A. Silverman, Y. Zhang and L. Z. Benet: Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci 87, 1322-1330(1998)
83. S. Ruetz and P. Gros: Phosphatidylcholine translocase: a physiological role for the mdr2 gene. Cell 77, 1071-1081(1994) (Pubitemid 24208866)
84. A. J. Smith, A. van Helvoort, G. van Meer, K. Szabo, E. Welker, G. Szakacs, A. Varadi, B. Sarkadi and P. Borst: MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem 275, 23530-23539(2000) (Pubitemid 30624635)
85. T. Gerloff, B. Stieger, B. Hagenbuch, J. Madon, L. Landmann, J. Roth, A. F. Hofmann and P. J. Meier: The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J Biol Chem 273, 10046-10050(1998) (Pubitemid 28183107)
86. J. A. Byrne, S. S. Strautnieks, G. Mieli-Vergani, C. F. Higgins, K. J. Linton and R. J. Thompson: The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology 123, 1649-1658(2002) (Pubitemid 35231664)
87. J. Noe, B. Stieger and P. J. Meier: Functional expression of the canalicular bile salt export pump of human liver. Gastroenterology 123, 1659-1666(2002) (Pubitemid 35231665)
88. V. Lecureur, D. Sun, P. Hargrove, E. G. Schuetz, R. B. Kim, L. B. Lan and J. D. Schuetz: Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol 57, 24-35(2000) (Pubitemid 30033256)
89. G. Jedlitschky, I. Leier, U. Buchholz, J. Hummel-Eisenbeiss, B. Burchell and D. Keppler: ATP-dependent transport of bilirubin glucuronides by the multidrug resistance protein MRP1 and its hepatocyte canalicular isoform MRP2. Biochem J 327, 305-310(1997) (Pubitemid 27455494)
90. A. T. Nies and D. Keppler: The apical conjugate efflux pump ABCC2 (MRP2). Pflugers Arch 453, 643-659(2007) (Pubitemid 46192536)
91. H. Akita, H. Suzuki, K. Ito, S. Kinoshita, N. Sato, H. Takikawa and Y. Sugiyama: Characterization of bile acid transport mediated by multidrug resistance associated protein 2 and bile salt export pump. Biochim Biophys Acta 1511, 7-16(2001) (Pubitemid 32206667)
92. D. Keppler, I. Leier and G. Jedlitschky: Transport of glutathione conjugates and glucuronides by the multidrug resistance proteins MRP1 and MRP2. Biol Chem 378, 787-791(1997) (Pubitemid 27388938)
93. P. K. Smitherman, A. J. Townsend, T. E. Kute and C. S. Morrow: Role of multidrug resistance protein 2 (MRP2, ABCC2) in alkylating agent detoxification: MRP2 potentiates glutathione S-transferase A1-1-mediated resistance to chlorambucil cytotoxicity. J Pharmacol Exp Ther 308, 260-267(2004) (Pubitemid 38090726)
94. J. Zhang, Q. Tian, S. Yung Chan, S. Chuen Li, S. Zhou, W. Duan and Y. Z. Zhu: Metabolism and transport of oxazaphosphorines and the clinical implications. Drug Metab Rev 37, 611-703(2005) (Pubitemid 43071142)
95. J. H. Hooijberg, H. J. Broxterman, M. Kool, Y. G. Assaraf, G. J. Peters, P. Noordhuis, R. J. Scheper, P. Borst, H. M. Pinedo and G. Jansen: Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res 59, 2532-2535(1999) (Pubitemid 29269093)
96. R. Evers, M. Kool, L. van Deemter, H. Janssen, J. Calafat, L. C. Oomen, C. C. Paulusma, R. P. Oude Elferink, F. Baas, A. H. Schinkel and P. Borst: Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J Clin Invest 101, 1310-1319(1998) (Pubitemid 28166828)
97. Y. Cui, J. Konig, J. K. Buchholz, H. Spring, I. Leier and D. Keppler: Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 55, 929-937(1999) (Pubitemid 29214613)
98. X. Y. Chu, Y. Kato and Y. Sugiyama: Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats. Cancer Res 57, 1934-1938(1997) (Pubitemid 27209724)
99. G. E. Sandusky, K. S. Mintze, S. E. Pratt and A. H. Dantzig: Expression of multidrug resistanceassociated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarrays. Histopathology 41, 65-74(2002) (Pubitemid 34779683)
100. J. Kartenbeck, U. Leuschner, R. Mayer and D. Keppler: Absence of the canalicular isoform of the MRP gene-encoded conjugate export pump from the hepatocytes in Dubin-Johnson syndrome. Hepatology 23, 1061-1066(1996)
101. C. M. Paumi, B. G. Ledford, P. K. Smitherman, A. J. Townsend and C. S. Morrow: Role of multidrug resistance protein 1 (MRP1) and glutathione S-transferase A1-1 in alkylating agent resistance. Kinetics of glutathione conjugate formation and efflux govern differential cellular sensitivity to chlorambucil versus melphalan toxicity. J Biol Chem 276, 7952-7956(2001)
102. C. S. Morrow, C. Peklak-Scott, B. Bishwokarma, T. E. Kute, P. K. Smitherman and A. J. Townsend: Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux. Mol Pharmacol 69, 1499-1505(2006)
103. T. Noguchi, X. Q. Ren, S. Aoki, Y. Igarashi, X. F. Che, Y. Nakajima, H. Takahashi, R. Mitsuo, K. Tsujikawa, T. Sumizawa, M. Haraguchi, M. Kobayashi, S. Goto, M. Kanehisa, T. Aikou, S. Akiyama and T. Furukawa: MRP1 mutated in the L0 region transports SN-38 but not leukotriene C4 or estradiol-17 (beta-D-glucuronate). Biochem Pharmacol 70, 1056-1065(2005) (Pubitemid 41262081)
104. C. E. Grant, G. Valdimarsson, D. R. Hipfner, K. C. Almquist, S. P. Cole and R. G. Deeley: Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 54, 357-361(1994) (Pubitemid 24053167)
105. M. Adachi, J. Sampath, L. B. Lan, D. Sun, P. Hargrove, R. Flatley, A. Tatum, M. Z. Edwards, M. Wezeman, L. Matherly, R. Drake and J. Schuetz: Expression of MRP4 confers resistance to ganciclovir and compromises bystander cell killing. J Biol Chem 277, 38998-39004(2002) (Pubitemid 35154766)
106. Z. S. Chen, K. Lee and G. D. Kruh: Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. J Biol Chem 276, 33747-33754(2001)
107. Z. S. Chen, K. Lee, S. Walther, R. B. Raftogianis, M. Kuwano, H. Zeng and G. D. Kruh: Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res 62, 3144-3150(2002) (Pubitemid 34602407)
108. Q. Tian, J. Zhang, T. M. Tan, E. Chan, W. Duan, S. Y. Chan, U. A. Boelsterli, P. C. Ho, H. Yang, J. S. Bian, M. Huang, Y. Z. Zhu, W. Xiong, X. Li and S. Zhou: Human multidrug resistance associated protein 4 confers resistance to camptothecins. Pharm Res 22, 1837-1853(2005) (Pubitemid 41504337)
109. N. Zelcer, T. Saeki, G. Reid, J. H. Beijnen and P. Borst: Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem 276, 46400-46407(2001)
110. J. Wijnholds, C. A. Mol, L. van Deemter, M. de Haas, G. L. Scheffer, F. Baas, J. H. Beijnen, R. J. Scheper, S. Hatse, E. De Clercq, J. Balzarini and P. Borst: Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci U S A 97, 7476-7481(2000) (Pubitemid 30431488)
111. J. Madon, B. Hagenbuch, L. Landmann, P. J. Meier and B. Stieger: Transport function and hepatocellular localization of mrp6 in rat liver. Mol Pharmacol 57, 634-641(2000) (Pubitemid 30140896)
112. A. A. Bergen, A. S. Plomp, X. Hu, P. T. de Jong and T. G. Gorgels: ABCC6 and pseudoxanthoma elasticum. Pflugers Arch 453, 685-691(2007) (Pubitemid 46192539)
113. M. G. Belinsky, Z. S. Chen, I. Shchaveleva, H. Zeng and G. D. Kruh: Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res 62, 6172-6177(2002) (Pubitemid 35244468)
114. E. Hopper-Borge, Z. S. Chen, I. Shchaveleva, M. G. Belinsky and G. D. Kruh: Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel. Cancer Res 64, 4927-4930(2004) (Pubitemid 38924539)
115. Z. S. Chen, Y. Guo, M. G. Belinsky, E. Kotova and G. D. Kruh: Transport of bile acids, sulfated steroids, estradiol 17-beta-D-glucuronide, and leukotriene C4 by human multidrug resistance protein 8 (ABCC11). Mol Pharmacol 67, 545-557(2005) (Pubitemid 40216748)
116. Y. Guo, E. Kotova, Z. S. Chen, K. Lee, E. Hopper-Borge, M. G. Belinsky and G. D. Kruh: MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2', 3'-dideoxycytidine and 9'-(2'-phosphonylmethoxyethyl) adenine. J Biol Chem 278, 29509-29514(2003) (Pubitemid 36962331)
117. G. D. Kruh, Y. Guo, E. Hopper-Borge, M. G. Belinsky and Z. S. Chen: ABCC10, ABCC11, and ABCC12. Pflugers Arch 453, 675-684(2007) (Pubitemid 46192538)
118. H. Kusuhara and Y. Sugiyama: ATP-binding cassette, subfamily G (ABCG family). Pflugers Arch 453, 735-744(2007) (Pubitemid 46192543)
119. K. E. Berge, H. Tian, G. A. Graf, L. Yu, N. V. Grishin, J. Schultz, P. Kwiterovich, B. Shan, R. Barnes and H. H. Hobbs: Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 290, 1771-1775(2000) (Pubitemid 32004809)
120. H. Wittenburg and M. C. Carey: Biliary cholesterol secretion by the twinned sterol halftransporters ABCG5 and ABCG8. J Clin Invest 110, 605-609(2002) (Pubitemid 34988782)
121. T. Litman, M. Brangi, E. Hudson, P. Fetsch, A. Abati, D. D. Ross, K. Miyake, J. H. Resau and S. E. Bates: The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci 113, 2011-2021(2000) (Pubitemid 30386505)
122. J. Xu, Y. Liu, Y. Yang, S. Bates and J. T. Zhang: Characterization of oligomeric human half-ABC transporter ATP-binding cassette G2. J Biol Chem 279, 19781-19789(2004) (Pubitemid 38623417)
123. L. A. Doyle, W. Yang, L. V. Abruzzo, T. Krogmann, Y. Gao, A. K. Rishi and D. D. Ross: A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A 95, 15665-15670(1998) (Pubitemid 29018757)
124. R. Allikmets, L. M. Schriml, A. Hutchinson, V. Romano-Spica and M. Dean: A human placentaspecific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 58, 5337-5339(1998) (Pubitemid 28551112)
125. M. A. Serrano, R. I. R. Macias, O. Briz, M. J. Monte, A. G. Blazquez, C. Williamson, R. Kubitz and J. J. G. Marin: Expression in human trophoblast and choriocarcinoma cell lines, BeWo, Jeg-3 and JAr of genes involved in the hepatobiliary-like excretory function of the placenta. Placenta 28, 107-117(2007) (Pubitemid 44914531)
126. M. Maliepaard, G. L. Scheffer, I. F. Faneyte, M. A. van Gastelen, A. C. Pijnenborg, A. H. Schinkel, M. J. van de Vijver, R. J. Scheper and J. H. Schellens: Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61, 3458-3464(2001) (Pubitemid 32695041)
127. P. Krishnamurthy, D. D. Ross, T. Nakanishi, K. Bailey-Dell, S. Zhou, K. E. Mercer, B. Sarkadi, B. P. Sorrentino and J. D. Schuetz: The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J Biol Chem 279, 24218-24225(2004) (Pubitemid 38725283)
128. Y. Imai, S. Asada, S. Tsukahara, E. Ishikawa, T. Tsuruo and Y. Sugimoto: Breast cancer resistance protein exports sulfated estrogens but not free estrogens. Mol Pharmacol 64, 610-618(2003) (Pubitemid 37048564)
129. T. Janvilisri, S. Shahi, H. Venter, L. Balakrishnan and H. W. van Veen: Arginine-482 is not essential for transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2). Biochem J 385, 419-426(2005) (Pubitemid 40165074)
130. E. L. Volk, K. Rohde, M. Rhee, J. J. McGuire, L. A. Doyle, D. D. Ross and E. Schneider: Methotrexate cross-resistance in a mitoxantroneselected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux. Cancer Res 60, 3514-3521(2000) (Pubitemid 30482171)
131. E. L. Volk and E. Schneider: Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res 63, 5538-5543(2003) (Pubitemid 37139875)
132. R. W. Robey, W. Y. Medina-Perez, K. Nishiyama, T. Lahusen, K. Miyake, T. Litman, A. M. Senderowicz, D. D. Ross and S. E. Bates: Overexpression of the ATP-binding cassette halftransporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin Cancer Res 7, 145-152(2001) (Pubitemid 32110217)
133. Y. Sugimoto, S. Tsukahara, Y. Imai, Y. Sugimoto, K. Ueda and T. Tsuruo: Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists. Mol Cancer Ther 2, 105-112(2003)
134. J. D. Allen, R. F. Brinkhuis, J. Wijnholds and A. H. Schinkel: The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res 59, 4237-4241(1999) (Pubitemid 29418735)
135. J. H. Schellens, M. Maliepaard, R. J. Scheper, G. L. Scheffer, J. W. Jonker, J. W. Smit, J. H. Beijnen and A. H. Schinkel: Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications. Ann N Y Acad Sci 922, 188-194(2000) (Pubitemid 32050253)
136. M. Maliepaard, M. A. van Gastelen, L. A. de Jong, D. Pluim, R. C. van Waardenburg, M. C. Ruevekamp-Helmers, B. G. Floot and J. H. Schellens: Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 59, 4559-4563(1999) (Pubitemid 29428958)
137. J. D. Allen, S. C. van Dort, M. Buitelaar, O. van Tellingen and A. H. Schinkel: Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Res 63, 1339-1344(2003) (Pubitemid 36348714)
138. H. Burger, H. van Tol, A. W. Boersma, M. Brok, E. A. Wiemer, G. Stoter and K. Nooter: Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 104, 2940-2942(2004) (Pubitemid 39434984)
139. K. Yanase, S. Tsukahara, J. Mitsuhashi and Y. Sugimoto: Functional SNPs of the breast cancer resistance protein-therapeutic effects and inhibitor development. Cancer Lett 234, 73-80(2006) (Pubitemid 43343941)
140. A. Tamura, K. Wakabayashi, Y. Onishi, M. Takeda, Y. Ikegami, S. Sawada, M. Tsuji, Y. Matsuda and T. Ishikawa: Re-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2. Cancer Sci 98, 231-239(2007) (Pubitemid 44941876)
141. Y. Honjo, C. A. Hrycyna, Q. W. Yan, W. Y. Medina-Perez, R. W. Robey, A. van de Laar, T. Litman, M. Dean and S. E. Bates: Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res 61, 6635-6639(2001) (Pubitemid 32896477)
142. Y. Imai, M. Nakane, K. Kage, S. Tsukahara, E. Ishikawa, T. Tsuruo, Y. Miki and Y. Sugimoto: C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 1, 611-616(2002)
143. S. Mizuarai, N. Aozasa and H. Kotani: Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2. Int J Cancer 109, 238-246(2004) (Pubitemid 38240926)
144. A. Sparreboom, H. Gelderblom, S. Marsh, R. Ahluwalia, R. Obach, P. Principe, C. Twelves, J. Verweij and L. H. McLeod: Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clin Pharmacol Ther 76, 38-44(2004) (Pubitemid 38844732)
145. L. A. Doyle, D. D. Ross: Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22, 7340-7358(2003) (Pubitemid 37487163)
146. J. M. Ford, W. N. Hait: Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev. 42, 155-199(1990) (Pubitemid 20291782)
147. W. T. Beck: Mechanisms of multidrug resistance in human tumor cells. The roles of P-glycoprotein, DNA topoisomerase II, and other factors. Cancer Treat Rev. 17, 11-20(1990)
148. W. T. Beck: Modulators of P-glycoproteinassociated multidrug resistance. Cancer Treat Res. 57, 151-170(1991)
149. M. Raderer, W. Scheithauer: Clinicals trials of agents that reverse multidrug resistance. A literature review. Cancer 72, 3553-3563(1993) (Pubitemid 24000587)
150. P. W. Wigler, F. K. Patterson: Inhibition of the multidrug resistance efflux pump. Biochim Biophys Acta. 1154, 173-181(1993) (Pubitemid 23316611)
151. C. Avendano, J. C. Menendez: Inhibitors of multidrug resistance to antitumor agents (MDR). Curr Med Chem. 9, 159-193(2002) (Pubitemid 34436440)
152. M. M. Gottesman, T. Fojo, S. E. Bates: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2, 48-58(2002) (Pubitemid 37328807)
153. J. M. Oude Terwogt, J. H. Beijnen, W. W. ten Bokkel Huinink, H. Rosing, J. H. Schellens: Coadministration of cyclosporin enables oral therapy with paclitaxel. Lancet 352, 285(1998) (Pubitemid 28340148)
154. B. L. Lum, S. Kaubisch, A. M. Yahanda, K. M. Adler, L. Jew, M. N. Ehsan, N. A. Brophy, J. Halsey, M. P. Gosland, B. I. Sikic: Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol. 10, 1635-1642(1992) (Pubitemid 23057994)
155. N. L. Bartlett, B. L. Lum, G. A. Fisher, N. A. Brophy, M. N. Ehsan, J. Halsey, B. I. Sikic: Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol. 12, 835-842(1994) (Pubitemid 24110926)
156. S. L. Berg, A. Tolcher, J. A. O'Shaughnessy, A. M. Denicoff, M. Noone, F. P. Ognibene, K. H. Cowan, F. M. Balis: Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer. J Clin Oncol. 13, 2039-2042(1995)
157. L. van Zuylen, A. Sparreboom, A. van der Gaast, K. Nooter, F. A. Eskens, E. Brouwer, C. J. Bol, R. de Vries, P. A. Palmer, J. Verweij: Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933. Eur J Cancer. 38, 1090-1099(2002) (Pubitemid 34468014)
158. S. Zhang, X. Wang, K. Sagawa, M. E. Morris: Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice. Drug Metab Dispos. 33, 341-348(2005) (Pubitemid 40279933)
159. R. M. Wadkins, P. J. Houghton: The role of druglipid interactions in the biological activity of modulators of multi-drug resistance. Biochim Biophys Acta. 1153, 225-236(1993) (Pubitemid 24028292)
160. C. W. Sachs, A. R. Safa, S. D. Harrison, R. L. Fine: Partial inhibition of multidrug resistance by safingol is independent of modulation of P-glycoprotein substrate activities and correlated with inhibition of protein kinase C. J Biol Chem. 270, 26639-26648(1995)
161. E. Gupta, A. R. Safa, X. Wang, M. J. Ratain: Pharmacokinetic modulation of irinotecan and metabolites by cyclosporine A. Cancer Res. 56, 1309-1314(1996) (Pubitemid 26080974)
162. M. Horikawa, Y. Kato, Y. Sugiyama: Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats. Pharm Res. 19, 1345-1353(2002)
163. K. Arimori, N. Kuroki, M. Hidaka, T. Iwakiri, K. Yamsaki, M. Okumura, H. Ono, N. Takamura, M. Kikuchi, M. Nakano: Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats. Pharm Res. 20, 910-917(2003) (Pubitemid 36628439)
164. K. Ueda, Y. Kato, K. Komatsu, Y. Sugiyama: Inhibition of biliary excretion of methotrexate by probenecid in rats: quantitative prediction of interaction from in vitro data. J Pharmacol Exp Ther. 297, 1036-1043(2001) (Pubitemid 32472501)
165. S. Childs, R. L. Yeh, D. Hui, V. Ling: Taxol resistance mediated by transfection of the liverspecific sister gene of P-glycoprotein. Cancer Res. 58, 4160-4167(1998) (Pubitemid 28440574)
166. R. K. Burt, S. S. Thorgeirsson: Coinduction of MDR-1 multidrug-resistance and cytochrome P-450 genes in rat liver by xenobiotics. J Natl Cancer Inst. 80, 1383-1386(1988)
167. T. W. Gant, J. A. Silverman, H. C. Bisgaard, R. K. Burt, P. A. Marino, S. S. Thorgeirsson: Regulation of 2-acetylaminofluorene-and 3-methylcholanthrene- mediated induction of multidrug resistance and cytochrome P450IA gene family expression in primary hepatocyte cultures and rat liver. Mol Carcinog. 4, 499-509(1991)
168. V. Lecureur, A. Guillouzo, O. Fardel: Differential regulation of mdr genes in response to 2-acetylaminofluorene treatment in cultured rat and human hepatocytes. Carcinogenesis 17, 1157-1160(1996) (Pubitemid 26158419)
169. V. Lecureur, J. V. Thottassery, D. Sun, E. G. Schuetz, J. Lahti, G. P. Zambetti, J. D. Schuetz: Mdr1b facilitates p53-mediated cell death and p53 is required for Mdr1b upregulation in vivo. Oncogene 20, 303-313(2001) (Pubitemid 32142319)
170. O. Fardel, L. Payen, A. Courtois, V. Lecureur, A. Guillouzo: Induction of multidrug resistance gene expression in rat liver cells in response to acute treatment by the DNA-damaging agent methyl methanesulfonate. Biochem Biophys Res Commun. 245, 85-89(1998) (Pubitemid 28414251)
171. K. N. Furuya, J. V. Thottassery, E. G. Schuetz, M. Sharif, J. D. Schuetz: Bromocriptine transcriptionally activates the multidrug resistance gene (pgp2/mdr1b) by a novel pathway. J Biol Chem. 272, 11518-11525(1997) (Pubitemid 27184162)
172. H. M. Kauffmann, D. Schrenk: Sequence analysis and functional characterization of the 5'-flanking region of the rat multidrug resistance protein 2 (mrp2) gene. Biochem Biophys Res Commun. 245, 325-331(1998) (Pubitemid 28418499)
173. Y. Kiuchi, H. Suzuki, T. Hirohashi, C. A. Tyson, Y. Sugiyama: cDNA cloning and inducible expression of human multidrug resistance associated protein 3 (MRP3). FEBS Lett. 433, 149-152(1998) (Pubitemid 28386747)
174. B. Stockel, J. Konig, A. T. Nies, Y. Cui, M. Brom, D. Keppler: Characterization of the 5'-flanking region of the human multidrug resistance protein 2 (MRP2) gene and its regulation in comparison withthe multidrug resistance protein 3 (MRP3) gene. Eur J Biochem. 267, 1347-1358(2000) (Pubitemid 30143273)
175. K. Ogawa, H. Suzuki, T. Hirohashi, T. Ishikawa, P. J. Meier, K. Hirose, T. Akizawa, M. Yoshioka, Y. Sugiyama: Characterization of inducible nature of MRP3 in rat liver. Am J Physiol Gastrointest Liver Physiol. 278, G438-446 (2000) (Pubitemid 30152490)
176. A. Courtois, L. Payen, L. Vernhet, F. Morel, A. Guillouzo, O. Fardel: Differential regulation of canalicular multispecific organic anion transporter (cMOAT) expression by the chemopreventive agent oltipraz in primary rat hepatocytes and in rat liver. Carcinogenesis 20, 2327-2330(1999) (Pubitemid 30015906)
177. A. M. Wielandt, V. Vollrath, M. Manzano, S. Miranda, L. Accatino, J. Chianale: Induction of the multispecific organic anion transporter (cMoat/mrp2) gene and biliary glutathione secretion by the herbicide 2, 4, 5-trichlorophenoxyacetic acid in the mouse liver. Biochem J. 341, 105-111(1999) (Pubitemid 29359053)
178. H. M. Kauffmann, D. Keppler, T. W. Gant, D. Schrenk: Induction of hepatic mrp2 (cmrp/cmoat) gene expression in nonhuman primates treated with rifampicin or tamoxifen. Arch Toxicol. 72, 763-768(1998) (Pubitemid 29048919)
179. T. W. Gant, J. A. Silverman, S. S. Thorgeirsson: Regulation of P-glycoprotein gene expression in hepatocyte cultures and liver cell lines by a transacting transcriptional repressor. Nucleic Acids Res. 20, 2841-2846(1992)
180. H. M. Kauffmann, D. Keppler, J. Kartenbeck, D. Schrenk: Induction of cMrp/cMoat gene expression by cisplatin, 2-acetylaminofluorene, or cycloheximide in rat hepatocytes. Hepatology 26, 980-985(1997) (Pubitemid 27413667)
181. Y. C. Lee, Y. K. Lai: Integrity of intermediate filaments is associated with the development of acquired thermotolerance in 9L rat brain tumor cells. J Cell Biochem. 57, 150-162(1995)
182. G. Conseil, H. Baubichon-Cortay, G. Dayan, J. M. Jault, D. Barron, A. Di Pietro: Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP-and steroid-binding sites on mouse P-glycoprotein. Proc Natl Acad Sci U S A. 95, 9831-9836(1998)
183. E. M. Leslie, Q. Mao, C. J. Oleschuk, R. G. Deeley, S. P. Cole: Modulation of multidrug resistance protein 1 (MRP1/ABCC1) transport and atpase activities by interaction with dietary flavonoids. Mol Pharmacol. 59, 1171-1180(2001) (Pubitemid 32381597)
184. S. Zhang, X. Yang, M. E. Morris: Combined effects of multiple flavonoids on breast cancer resistance protein (ABCG2)-mediated transport. Pharm Res. 21, 1263-1273(2004) (Pubitemid 38954213)
185. S. Zhang, X. Yang, M. E. Morris: Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol Pharmacol. 65, 1208-1216(2004) (Pubitemid 38543491)
186. G. Scambia, F. O. Ranelletti, P. B. Panici, R. De Vincenzo, G. Bonanno, G. Ferrandina, M. Piantelli, S. Bussa, C. Rumi, M. Cianfriglia, et al.: Quercetin potentiates the effect of adriamycin in a multidrugresistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target. Cancer Chemother Pharmacol. 34, 459-464(1994) (Pubitemid 24306043)
187. J. W. Critchfield, C. J. Welsh, J. M. Phang, G. C. Yeh: Modulation of adriamycin accumulation and efflux by flavonoids in HCT-15 colon cells. Activation of P-glycoprotein as a putative mechanism. Biochem Pharmacol. 48, 1437-1445(1994)
188. A. F. Castro, G. A. Altenberg: Inhibition of drug transport by genistein in multidrug-resistant cells expressing P-glycoprotein. Biochem Pharmacol. 53, 89-93(1997) (Pubitemid 26419790)
189. S. Zhang, M. E. Morris: Effect of the flavonoids biochanin A and silymarin on the P-glycoproteinmediated transport of digoxin and vinblastine in human intestinal Caco-2 cells. Pharm Res. 20, 1184-1191(2003) (Pubitemid 36951843)
190. S. Zhang, M. E. Morris: Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther. 304, 1258-1267(2003) (Pubitemid 36254439)
191. Y. Mitsunaga, H. Takanaga, H. Matsuo, M. Naito, T. Tsuruo, H. Ohtani, Y. Sawada: Effect of bioflavonoids on vincristine transport across bloodbrain barrier. Eur J Pharmacol. 395, 193-201(2000) (Pubitemid 30254368)
192. J. S. Choi, H. K. Choi, S. C. Shin: Enhanced bioavailability of paclitaxel after oral coadministration with flavone in rats. Int J Pharm. 275, 165-170(2004)
193. J. S. Choi, B. W. Jo, Y. C. Kim: Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin. Eur J Pharm Biopharm. 57, 313-318(2004)
194. C. H. Versantvoort, G. J. Schuurhuis, H. M. Pinedo, C. A. Eekman, C. M. Kuiper, J. Lankelma, H. J. Broxterman: Genistein modulates the decreased drug accumulation in non-P-glycoprotein mediated multidrug resistant tumour cells. Br J Cancer. 68, 939-946(1993) (Pubitemid 23315227)
195. C. H. Versantvoort, H. J. Broxterman, J. Lankelma, N. Feller, H. M. Pinedo: Competitive inhibition by genistein and ATP dependence of daunorubicin transport in intact MRP overexpressing human small cell lung cancer cells. Biochem Pharmacol. 48, 1129-1136(1994) (Pubitemid 24298363)
196. H. Nguyen, S. Zhang, M. E. Morris: Effect of flavonoids on MRP1-mediated transport in Panc-1 cells. J Pharm Sci. 92, 250-257(2003) (Pubitemid 36169297)
197. J. J. van Zanden, L. Geraets, H. M. Wortelboer, P. J. van Bladeren, I. M. Rietjens, N. H. Cnubben: Structural requirements for the flavonoid-mediated modulation of glutathione S-transferase P1-1 and GS-X pump activity in MCF7 breast cancer cells. Biochem Pharmacol. 67, 1607-1617(2004) (Pubitemid 38388223)
198. H. C. Cooray, T. Janvilisri, H. W. van Veen, S. B. Hladky, M. A. Barrand: Interaction of the breast cancer resistance protein with plant polyphenols. Biochem Biophys Res Commun. 317, 269-275(2004) (Pubitemid 38401995)
199. Y. Imai, S. Tsukahara, S. Asada, Y. Sugimoto: Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Res. 64, 4346-4352(2004) (Pubitemid 38802442)
200. Y. Ji, M. E. Morris: Effect of organic isothiocyanates on breast cancer resistance protein (ABCG2)-mediated transport. Pharm Res. 21, 2261-2269(2004) (Pubitemid 40568440)
201. H. Takanaga, A. Ohnishi, H. Matsuo, Y. Sawada: Inhibition of vinblastine efflux mediated by P-glycoprotein by grapefruit juice components in caco-2 cells. Biol Pharm Bull. 21, 1062-1066(1998) (Pubitemid 28513983)
202. S. Reif, M. C. Nicolson, D. Bisset, M. Reid, C. Kloft, U. Jaehde, H. L. McLeod: Effect of grapefruit juice intake on etoposide bioavailability. Eur J Clin Pharmacol. 58, 491-494(2002) (Pubitemid 35244924)
203. A. Soldner, U. Christians, M. Susanto, V. J. Wacher, J. A. Silverman, L. Z. Benet: Grapefruit juice activates P-glycoprotein-mediated drug transport. Pharm Res. 16, 478-485(1999) (Pubitemid 29191290)
204. X. Wang, A. W. Wolkoff, M. E. Morris: Flavonoids as a novel class of human organic aniontransporting polypeptide OATP1B1 (OATP-C) modulators. Drug Metab Dispos. 33, 1666-1672(2005) (Pubitemid 41539965)
205. A. F. List, C. Spier, J. Greer, S. Wolff, J. Hutter, R. Dorr, S. Salmon, B. Futscher, M. Baier, W. Dalton: Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol. 11, 1652-1660(1993) (Pubitemid 23277315)
206. G. R. Villanueva, M. E. Mendoza, M. Y. el-Mir, M. J. Monte, M. C. Herrera, J. J. Marin: Effect of bile acids on hepatobiliary transport of cisplatin by perfused rat liver. Pharmacol Toxicol. 80, 111-117(1997) (Pubitemid 27119799)
207. C. P. Yang, S. G. De Pinho, L. M. Greenberger, R. J. Arceci, S. B. Horwitz: Progesterone interacts with P-glycoprotein in multidrug-resistant cells and in the endometrium of gravid uterus. J Biol Chem. 264, 782-788(1989) (Pubitemid 19038053)
208. K. Ueda, N. Okamura, M. Hirai, Y. Tanigawara, T. Saeki, N. Kioka, T. Komano, R. Hori: Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem. 267, 24248-24252(1992)
209. X. D. Qian, W. T. Beck: Progesterone photoaffinity labels P-glycoprotein in multidrugresistant human leukemic lymphoblasts. J Biol Chem. 265, 18753-18756(1990)
210. J. Kirk, S. Houlbrook, N. S. Stuart, I. J. Stratford, A. L. Harris, J. Carmichael: Selective reversal of vinblastine resistance in multidrug-resistant cell lines by tamoxifen, toremifene and their metabolites. Eur J Cancer. 29 A, 1152-1157 (1993) (Pubitemid 23156641)
211. V. Lecureur, O. Fardel, A. Guillouzo: The antiprogestatin drug RU 486 potentiates doxorubicin cytotoxicity in multidrug resistant cells through inhibition of P-glycoprotein function. FEBS Lett. 355, 187-191(1994) (Pubitemid 24355116)
212. G. Zhou, M. T. Kuo: NF-kappaB-mediated induction of mdr1b expression by insulin in rat hepatoma cells. J Biol Chem. 272, 15174-15183(1997) (Pubitemid 27255533)
213. K. I. Hirsch-Ernst, C. Ziemann, C. Schmitz-Salue, H. Foth, G. F. Kahl: Modulation of P-glycoprotein and mdr1b mRNA expression by growth factors in primary rat hepatocyte culture. Biochem Biophys Res Commun. 215, 179-185(1995)
214. A. L. Russell, C. J. Henderson, G. Smith, C. R. Wolf: Suppression of multi-drug resistance gene expression in the mouse liver by 1, 4-bis[2, (3, 5-dichloropyridyloxy)] benzene. Int J Cancer. 58, 550-554(1994) (Pubitemid 24268098)
215. A. Courtois, L. Payen, A. Guillouzo, O. Fardel: Up-regulation of multidrug resistance-associated protein 2 (MRP2) expression in rat hepatocytes by dexamethasone. FEBS Lett. 459, 381-385(1999) (Pubitemid 29467372)
216. U Warskulat, R Kubitz, M Wettstein, B Stieger, PJ Meier, D Haussinger: Regulation of bile salt export pump mRNA levels by dexamethasone and osmolarity in cultured rat hepatocytes. Biol Chem. 380, 1273-1279(1999)
217. Y. Liu, F. J. Suchy, J. A. Silverman, M. Vore: Prolactin increases ATP-dependent taurocholate transport in canalicular plasma membrane from rat liver. Am J Physiol. 272, G46-53 (1997)
218. J. Cao, L. Huang, Y. Liu, T. Hoffman, B. Stieger, P. J. Meier, M. Vore: Differential regulation of hepatic bile salt and organic anion transporters in pregnant and postpartum rats and the role of prolactin. Hepatology 33, 140-147(2001) (Pubitemid 32016896)
219. J. B. Mitchell, J. A. Cook, W. De Graff, E. Glatstein, A. Russo: Glutathione modulation in cancer treatment: will it work? Int J Radiat Oncol Biol Phys. 16, 1289-1295(1989) (Pubitemid 19137231)
220. D. W. Loe, R. G. Deeley, S. P. Cole: Characterization of vincristine transport by the M (r) 190, 000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. Cancer Res. 58, 5130-5136(1998) (Pubitemid 28521173)
221. C. C. Huang, M. C. Wu, G. W. Xu, D. Z. Li, H. Cheng, Z. X. Tu, H. Q. Jiang and J. R. Gu: Overexpression of the MDR1 gene and P-glycoprotein in human hepatocellular carcinoma. J Natl Cancer Inst 84, 262-264(1992)
222. E. G. Schuetz, K. N. Furuya and J. D. Schuetz: Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J Pharmacol Exp Ther 275, 1011-1018(1995) (Pubitemid 26023635)
223. P. M. Chaudhary and I. B. Roninson: Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst 85, 632-639(1993) (Pubitemid 23120508)
224. D. Schrenk, A. Michalke, T. W. Gant, P. C. Brown, J. A. Silverman and S. S. Thorgeirsson: Multidrug resistance gene expression in rodents and rodent hepatocytes treated with mitoxantrone. Biochem Pharmacol 52, 1453-1460(1996) (Pubitemid 26366371)
225. O. Fardel, V. Lecureur, S. Daval, A. Corlu and A. Guillouzo: Up-regulation of P-glycoprotein expression in rat liver cells by acute doxorubicin treatment. Eur J Biochem 246, 186-192(1997) (Pubitemid 27229686)
226. D. Schrenk, P. R. Baus, N. Ermel, C. Klein, B. Vorderstemann and H. M. Kauffmann: Up-regulation of transporters of the MRP family by drugs and toxins. Toxicology Letters 120, 51-57(2001) (Pubitemid 32375070)
227. C. Ziemann, A. Burkle, G. F. Kahl and K. I. Hirsch-Ernst: Reactive oxygen species participate in mdr1b mRNA and P-glycoprotein overexpression in primary rat hepatocyte cultures. Carcinogenesis 20, 407-414(1999) (Pubitemid 29112627)
228. G. Zhou and M. T. Kuo: Wild-type p53-mediated induction of rat mdr1b expression by the anticancer drug daunorubicin. J Biol Chem 273, 15387-15394(1998) (Pubitemid 28298143)
229. Y. E. Timsit and M. Negishi: CAR and PXR: the xenobiotic-sensing receptors. Steroids 72, 231-246(2007) (Pubitemid 46273513)
230. R. G. Tirona and R. B. Kim: Nuclear receptors and drug disposition gene regulation. J Pharm Sci 94, 1169-1186(2005) (Pubitemid 40904182)
231. H. R. Kast, B. Goodwin, P. T. Tarr, S. A. Jones, A. M. Anisfeld, C. M. Stoltz, P. Tontonoz, S. Kliewer, T. M. Willson and P. A. Edwards: Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem 277, 2908-2915(2002) (Pubitemid 34953324)
232. M. Assem, E. G. Schuetz, M. Leggas, D. Sun, K. Yasuda, G. Reid, N. Zelcer, M. Adachi, S. Strom, R. M. Evans, D. D. Moore, P. Borst and J. D. Schuetz: Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice. J Biol Chem 279, 22250-22257(2004) (Pubitemid 38679421)
233. O. Burk, K. A. Arnold, A. Geick, H. Tegude and M. Eichelbaum: A role for constitutive androstane receptor in the regulation of human intestinal MDR1 expression. Biol Chem 386, 503-513(2005) (Pubitemid 41447572)
234. A. Geick, M. Eichelbaum and O. Burk: Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 276, 14581-14587(2001)
235. T. W. Synold, I. Dussault and B. M. Forman: The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 7, 584-590(2001) (Pubitemid 32448326)
236. J. L. Staudinger, A. Madan, K. M. Carol and A. Parkinson: Regulation of drug transporter gene expression by nuclear receptors. Drug Metab Dispos 31, 523-527(2003) (Pubitemid 36444159)
237. S. Teng, V. Jekerle and M. Piquette-Miller: Induction of ABCC3 (MRP3) by pregnane X receptor activators. Drug Metab Dispos 31, 1296-1299(2003) (Pubitemid 37310315)
238. G. L. Guo, J. Staudinger, K. Ogura and C. D. Klaassen: Induction of rat organic anion transporting polypeptide 2 by pregnenolone-16alpha-carbonitrile is via interaction with pregnane X receptor. Mol Pharmacol 61, 832-839(2002) (Pubitemid 34273163)
239. H. Masuyama, N. Suwaki, Y. Tateishi, H. Nakatsukasa, T. Segawa and Y. Hiramatsu: The pregnane X receptor regulates gene expression in a ligand-and promoter-selective fashion. Mol Endocrinol 19, 1170-1180(2005) (Pubitemid 40594117)
240. E. Schuetz, L. Lan, K. Yasuda, R. Kim, T. A. Kocarek, J. Schuetz and S. Strom: Development of a realtime in vivo transcription assay: application reveals pregnane X receptor-mediated induction of CYP3A4 by cancer chemotherapeutic agents. Mol Pharmacol 62, 439-445(2002) (Pubitemid 36329360)
241. S. Donald, R. D. Verschoyle, R. Edwards, D. J. Judah, R. Davies, J. Riley, D. Dinsdale, L. Lopez Lazaro, A. G. Smith, T. W. Gant, P. Greaves and A. J. Gescher: Hepatobiliary damage and changes in hepatic gene expression caused by the antitumor drug ecteinascidin-743 (ET-743) in the female rat. Cancer Res 62, 4256-4262(2002) (Pubitemid 34827280)
242. M. Demeule, M. Brossard, S. Turcotte, A. Regina, J. Jodoin and R. Beliveau: Diallyl disulfide, a chemopreventive agent in garlic, induces multidrug resistance-associated protein 2 expression. Biochem Biophys Res Commun 324, 937-945(2004) (Pubitemid 39345604)
243. C. D. Fisher, L. M. Augustine, J. M. Maher, D. M. Nelson, A. L. Slitt, C. D. Klaassen, L. D. Lehman-McKeeman and N. J. Cherrington: Induction of drug-metabolizing enzymes by garlic and allyl sulfide compounds via activation of constitutive androstane receptor and nuclear factor E2-related factor 2. Drug Metab Dispos 35, 995-1000(2007) (Pubitemid 46798610)
244. M. M. Gottardis, E. D. Bischoff, M. A. Shirley, M. A. Wagoner, W. W. Lamph and R. A. Heyman: Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Cancer Res 56, 5566-5570(1996) (Pubitemid 26422151)
245. Y. Wang, R. Yao, A. Maciag, C. J. Grubbs, R. A. Lubet and M. You: Organ-specific expression profiles of rat mammary gland, liver, and lung tissues treated with targretin, 9-cis retinoic acid, and 4-hydroxyphenylretinamide. Mol Cancer Ther 5, 1060-1072(2006) (Pubitemid 43724607)
246. M. Ananthanarayanan, N. Balasubramanian, M. Makishima, D. J. Mangelsdorf and F. J. Suchy: Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J Biol Chem 276, 28857-28865(2001)
247. R. Kroker, M. S. Anwer and D. Hegner: A compartmental model for hepatic transport of taurocholic acid in isolated perfused rat liver. Naunyn Schmiedebergs Arch Pharmacol 303, 287-293(1978) (Pubitemid 8379214)
248. P. von Dippe and D. Levy: Expression of the bile acid transport protein during liver development and in hepatoma cells. J Biol Chem 265, 5942-5945(1990)
249. P. Marchegiano, F. Carubbi, C. Tiribelli, S. Amarri, M. Stebel, G. C. Lunazzi, D. Levy and S. Bellentani: Transport of sulfobromophthalein and taurocholate in the HepG2 cell line in relation to the expression of membrane carrier proteins. Biochem Biophys Res Commun 183, 1203-1208(1992)
250. G. A. Kullak-Ublick, U. Beuers and G. Paumgartner: Molecular and functional characterization of bile acid transport in human hepatoblastoma HepG2 cells. Hepatology 23, 1053-1060(1996) (Pubitemid 26137046)
251. Y. Cui, J. Konig, A. T. Nies, M. Pfannschmidt, M. Hergt, W. W. Franke, W. Alt, R. Moll and D. Keppler: Detection of the human organic anion transporters SLC21A6 (OATP2) and SLC21A8 (OATP8) in liver and hepatocellular carcinoma. Lab Invest 83, 527-538(2003) (Pubitemid 36457707)
252. A. Libra, C. Fernetti, V. Lorusso, M. Visigalli, P. L. Anelli, F. Staud, C. Tiribelli and L. Pascolo: Molecular determinants in the transport of a bile acid-derived diagnostic agent in tumoral and nontumoral cell lines of human liver. J Pharmacol Exp Ther 319, 809-817(2006)
253. M. J. Monte, S. Dominguez, M. F. Palomero, R. I. R. Macias and J. J. G. Marin: Further evidence for the usefulness of bile acids as carrier molecules for cytostatic drugs toward liver tumors. J Hepatol 31, 521-528(1999) (Pubitemid 29408737)
254. G. Zollner, M. Wagner, P. Fickert, D. Silbert, A. Fuchsbichler, K. Zatloukal, H. Denk and M. Trauner: Hepatobiliary transporter expression in human hepatocellular carcinoma. Liver Int 25, 367-379(2005)
255. M. R. Ballestero, M. J. Monte, O. Briz, F. Jimenez, F. Gonzalez-San Martin and J. J. G. Marin: Expression of transporters potentially involved in the targeting of cytostatic bile acid derivatives to colon cancer and polyps. Biochem Pharmacol 72, 729-738(2006) (Pubitemid 44233549)
256. S. Van der Borght, L. Libbrecht, H. Blokzijl, K. N. Faber, H. Moshage, R. Aerts, W. Van Steenbergen, P. L. Jansen, V. J. Desmet and T. A. Roskams: Diagnostic and pathogenetic implications of the expression of hepatic transporters in focal lesions occurring in normal liver. J Pathol 207, 471-482(2005) (Pubitemid 43025696)
257. H. Kojima, A. T. Nies, J. Konig, W. Hagmann, H. Spring, M. Uemura, H. Fukui and D. Keppler: Changes in the expression and localization of hepatocellular transporters and radixin in primary biliary cirrhosis. J Hepatol 39, 693-702(2003) (Pubitemid 37372176)
258. G. Zollner, P. Fickert, D. Silbert, A. Fuchsbichler, H. U. Marschall, K. Zatloukal, H. Denk and M. Trauner: Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J Hepatol 38, 717-727(2003) (Pubitemid 36613336)
259. O. Briz, R. I. R. Macias, M. Vallejo, A. Silva, M. A. Serrano and J. J. G. Marin: Usefulness of liposome-encapsulated cytostatic bile acid derivatives to circumvent chemotherapy resistance of enterohepatic tumors. Mol Pharmacol 63, 742-750(2003) (Pubitemid 36297348)
260. M. G. Larena, M. C. Martinez-Diez, R. I. R. Macias, M. F. Dominguez, M. A. Serrano and J. J. G. Marin: Relationship between tumor cell load and sensitivity to cytostatic effect of two novel platinumbile acid complexes, Bamet-D3 and Bamet-UD2. J Drug Target 10, 397-404(2002)
261. J. J. G. Marin, M. R. Romero, M. Vallejo and M. J. Monte: Targeting of cytostatic bile acid derivatives toward tumours of the enterohepatic circuit. Cancer Ther 3, 57-64(2005)
262. J. J. G. Marin, M. R. Romero, M. Vallejo, M. J. Perez and O. Briz: Emerging interest of bile acid transporters in Pathophysiology and Pharmacology. Med Hypoth Res 2, 425-448(2005)
263. E. Sievänen: Exploitation of bile acid transport systems in prodrug design. Molecules 12, 1-29(2007)
264. S. Mukhopadhyay and U. Maitra: Chemistry and biology of bile acids. Curr Sci 87, 1666-1683(2004) (Pubitemid 41024553)
265. N. F. H. Ho: Utilizing bile acid carrier mechanisms to enhance liver and small intestine absorption. Ann NY Acad Sci 907, 315-329(1987)
266. D. A. Betebenner, P. L. Carney, A. M. Zimmer and J. M. Kazikiewicz: Hepatobiliary delivery of polyaminopolycarboxylate chelates: Synthesis and characterization of a cholic acid conjugate of EDTA and biodistribution and imaging studies with its indium-111 chelate. Bioconjug Chem 2, 117-123(1991)
267. Z. F. Stephan, E. C. Yurachek, R. Sharif, J. M. Wasvary, R. E. Steele and C. Howes. Reduction of cardiovascular and thyroxine-suppressing activities of L-T3 by liver targeting with cholic acid. Biochem Pharmacol 43, 1969-1974(1992)
268. W. Kramer and G. Wess: Bile acid transport systems as pharmaceutical targets. Eur J Clin Invest 26, 715-732(1996) (Pubitemid 26308644)
269. W. Kramer, F. Girbig, H. Glombik, D. Corsiero, S. Stengelin and C. Weyland: Identification of a ligand-binding site in the Na+/bile acid cotransporting protein from rabbit ileum. J Biol Chem 276, 36020-36027(2001)
270. W. Kramer, G. Wess, G. Schubert, M. Bickel, F. Girbig, U. Gutjahr, S. Kowalewski, K. H. Baringhaus, A. Enhsen, H. Glombik, S. Mullner, G. Neckermann, S. Schulz and E. Petzinger: Liverspecific drug targeting by coupling to bile acids. J Biol Chem 267, 18598-18604(1992)
271. I. M. Eunok, H. C. Yung, P. Kee-Joo, S. Hongsuk, J. Youngeup, K. Kyu-Won, H. Y. Young and D. K. Nam: Novel bile acid derivatives induce apoptosis via a p53-independent pathway in human breast carcinoma cells. Cancer Letters 163, 83-93(2001)
272. F. M. Muggia: Cisplatin update. Semin Oncol 18, 1-4(1991)
273. J. J. Criado, R. I. R. Macias, M. Medarde, M. J. Monte, M. A. Serrano and J. J. G. Marin. Synthesis and characterization of the new cytostatic complex cis-diammineplatinum (II)-chlorocholylglycinate. Bioconjug Chem 8, 453-458(1997) (Pubitemid 27347549)
274. J. J. Criado, M. F. Dominguez, M. Medarde, E. R. Fernandez, R. I. R. Macias and J. J. G. Marin: Structural characterization, kinetic studies, and in vitro biological activity of new cis-diamminebischolylglycinate (O, O') Pt (II) and cis-diamminebisursodeoxycholate (O, O') Pt (II) complexes. Bioconjug Chem 11, 167-174(2000) (Pubitemid 30174483)
275. J. Carrasco, J. J. Criado, R. I. R. Macias, J. L. Manzano, J. J. G. Marin, M. Medarde and E. Rodriguez: Structural characterization and cytostatic activity of chlorobischolylglycinatogold (III). J Inorg Chem 84, 287-292(2001) (Pubitemid 33733455)
276. R. Paschke, J. Kalbitz, C. Paetz, M. Luckner, T. Mueller, H.-J. Schmoll, H. Mueller, E. Sorkau and E. Sinn: Cholic acid-carboplatin compounds (CarboChAPt) as models for specific drug delivery: synthesis of novel carboplatin analogous derivatives and comparison of the cytotoxic properties with corresponding cisplatin compounds. J Inorg Biochem 94, 335-342(2003) (Pubitemid 36349500)
277. M. Maeda, N. Takasuka, T. Suga and T. Sasaki: New antitumor platinum (II) complexes with both lipophilicity and water miscibility. Japan J Cancer Res 81, 567-569(1990) (Pubitemid 20236570)
278. R. I. R. Macias, M. J. Monte, M. Y. El-Mir, G. R. Villanueva and J. J. G. Marin: Transport and biotransformation of the new cytostatic complex cisdiammineplatinum (II)-chlorocholylglycinate (Bamet-R2) by the rat liver. J Lipid Res 39, 1792-1798(1998) (Pubitemid 28411166)
279. M. G. Larena, M. C. Martinez-Diez, M. J. Monte, M. F. Dominguez, M. J. Pascual and J. J. G. Marin: Liver organotropism and biotransformation of a novel platinum-ursodeoxycholate derivative, Bamet-UD2, with enhanced antitumor activity. J Drug Target 9, 185-200(2001) (Pubitemid 32776366)